2012
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors
Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors. Investigational New Drugs 2012, 30: 2364-2370. PMID: 22331549, PMCID: PMC3703248, DOI: 10.1007/s10637-012-9800-3.Peer-Reviewed Original ResearchConceptsNeutropenic sepsisGrade 4 febrile neutropeniaDoses of ixabepiloneAdvanced solid tumorsExcellent performance statusPhase I trialSerial plasma samplesPlasma drug concentrationsRefractory advanced cancersHigh inter-individual variabilityFebrile neutropeniaPerformance statusI trialMedian ageAdvanced cancerInter-individual variabilityOral dosesSafety profileCohort 2Cohort 1Cohort 3PK variabilityOral formulationIxabepilonePatients
2010
Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
Kunz PL, Fisher GA. Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. Clinical And Experimental Gastroenterology 2010, Volume 3: 79-86. PMID: 21694850, PMCID: PMC3108662, DOI: 10.2147/ceg.s5928.Peer-Reviewed Original ResearchGastroenteropancreatic neuroendocrine tumorsSomatostatin analoguesNeuroendocrine tumorsTumor growthExcellent performance statusMainstay of treatmentNon-surgical therapyEnd-organ effectsExternal beam radiationNovel therapeutic trialsTyrosine kinase inhibitorsEarly promising resultsSecretion of peptidesSystemic chemotherapyLocoregional therapyPerformance statusMetastatic diseaseStandard chemotherapySurgical resectionMedical therapyTherapeutic trialsGEP-NETsTumor massMTOR inhibitorsAngiogenesis inhibitors